Answers are grounded in this paper and cite their sources.
To evaluate in vivo efficacy of nonclinical surrogate PRX123 (PRX123s) – a dual amyloid beta (Aβ)/tau peptide vaccine against the N-terminus of Aβ and MTBR-tau – in a transgenic mouse model expressing human amyloid precursor protein (APP) and with aggressively high Aβ pathology.
No takes yet. Share an insight, caveat, or question.
Barbour et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: